Sutro Biopharma, Inc.
NASDAQ:STRO
Overview | Financials
Company Name | Sutro Biopharma, Inc. |
Symbol | STRO |
Currency | USD |
Price | 1.72 |
Market Cap | 141,828,964 |
Dividend Yield | 0% |
52-week-range | 1.67 - 6.13 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. William J. Newell J.D. |
Website | https://www.sutrobio.com |
An error occurred while fetching data.
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD